Literature DB >> 11755920

Expression of tissue transglutaminase and elafin in human coronary artery: implication for plaque instability.

Yoshihiko Sumi1, Nobutaka Inoue, Hiroshi Azumi, Tadashi Seno, Masanori Okuda, Ken-ichi Hirata, Seinosuke Kawashima, Yoshitake Hayashi, Hiroshi Itoh, Mitsuhiro Yokoyama.   

Abstract

BACKGROUND: the extracellular matrix (ECM) is an important determinant of plaque instability. Since tissue transglutaminase (tTG) and elafin act as stabilizing factors, they might play a crucial role in the pathogenesis of acute coronary syndrome. We examined their expression in human coronary arteries and the regulation of tTG expression in cultured vascular smooth muscle cells (SMCs). METHODS AND
RESULTS: immunohistochemical studies on autopsy samples of human coronary arteries revealed the expression of tTG and elafin in the endothelium, medial SMCs, and the ECM in non-atherosclerotic coronary arteries. Their expression in SMCs, endothelium, and ECM was enhanced in atherosclerotic coronary arteries. In contrast, they were hardly detectable in accumulating macrophages or at the lipid core. Double staining demonstrated that elafin was co-localized with tTG. Moreover, some tTG-expressing cells were positive for TNF-alpha, suggesting that this cytokine might play an important role in the regulation of tTG. Treatment of cultured rat aortic SMCs with TNF-alpha increased their tTG mRNA, protein expression and enzyme activity.
CONCLUSIONS: the expression of tTG and elafin increased in atherosclerotic coronary arteries. The investigation with cultured SMCs suggested that TNF-alpha might mediate the upregulation of tTG. Our findings may provide new insights into the mechanism of plaque instability and the pathogenesis of acute coronary syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11755920     DOI: 10.1016/s0021-9150(01)00542-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  Roles of transglutaminases in cardiac and vascular diseases.

Authors:  David C Sane; Jimmy L Kontos; Charles S Greenberg
Journal:  Front Biosci       Date:  2007-01-01

2.  Transglutaminase 2-mediated activation of β-catenin signaling has a critical role in warfarin-induced vascular calcification.

Authors:  Kelly E Beazley; Stephanie Deasey; Florence Lima; Maria V Nurminskaya
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

Review 3.  Secretory leukocyte protease inhibitor promising protective roles in obesity-associated atherosclerosis.

Authors:  Qiao-Qing Zhong; Xiang Wang; Yun-Feng Li; Li-Jun Peng; Zhi-Sheng Jiang
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-04

4.  Arterial vimentin is a transglutaminase substrate: a link between vasomotor activity and remodeling?

Authors:  Madhu Gupta; Charles S Greenberg; Delrae M Eckman; David C Sane
Journal:  J Vasc Res       Date:  2007-05-03       Impact factor: 1.934

5.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

6.  Calcification locates to transglutaminases in advanced human atherosclerotic lesions.

Authors:  Hanke L Matlung; Harald C Groen; Judith de Vos; Theo van Walsum; Aad van der Lugt; Wiro J Niessen; Jolanda J Wentzel; Ed Vanbavel; Erik N T P Bakker
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

Review 7.  Inflammation, Autoimmunity, and Hypertension: The Essential Role of Tissue Transglutaminase.

Authors:  Chen Liu; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2017-08-01       Impact factor: 2.689

8.  Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension.

Authors:  Chen Liu; Renna Luo; Wei Wang; Zhangzhe Peng; Gail V W Johnson; Rodney E Kellems; Yang Xia
Journal:  Am J Hypertens       Date:  2019-04-22       Impact factor: 2.689

9.  Transglutaminase 2 moderates the expansion of mouse abdominal aortic aneurysms.

Authors:  Kathryn J Griffin; Kingsley R Simpson; Cora M L Beckers; Laura M Newell; Lih T Cheah; Nadira Y Yuldasheva; Siiri Iismaa; Christopher L Jackson; Julian D A Scott; Richard J Pease
Journal:  JVS Vasc Sci       Date:  2021-05-18

10.  Elafin inhibits obesity, hyperglycemia, and liver steatosis in high-fat diet-treated male mice.

Authors:  Jiani Wang; Christina Ortiz; Lindsey Fontenot; Riya Mukhopadhyay; Ying Xie; Ivy Ka Man Law; David Q Shih; S Anjani Mattai; Zhaoping Li; Hon Wai Koon
Journal:  Sci Rep       Date:  2020-07-30       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.